

For Immediate Release

TSX Exchange Symbol: RVX

**Resverlogix Presents Key Apo-AI/HDL Scientific Data at DALM**

Calgary, AB, October 4, 2007 – Resverlogix Corp. (“Resverlogix”) (TSX:RVX) is pleased to announce today that the Company is making an oral presentation of key scientific data of its lead clinical candidate, RVX-208, at the 16<sup>th</sup> International Symposium for Drugs Affecting Lipid Metabolism (DALM). The presentation titled, “A novel drug RVX-208 raises plasma apolipoprotein A-I and HDL cholesterol”, will be presented by Dr. Norman Wong on October 4, 2007 at the Hilton Hotel in New York City.

“DALM is a premier international conference renowned for its content of state of the art therapeutics for the prevention of atherosclerosis and other cardiovascular diseases. We are pleased that Resverlogix will present its data detailing RVX-208, a small molecule drug which enhances the production of ApoA-I and HDL,” stated Dr. Jan Johansson, Senior Vice President of Clinical Affairs of Resverlogix. Dr. Johansson added, “The scientific community recognizes the importance of a small molecule in the form of an oral tablet that significantly increases ApoA-I production, thereby enhancing the function of HDL. These beneficial effects of RVX-208 will potentially reduce the risk of atherosclerosis and cardiovascular disease.”

**About Resverlogix Corp.**

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas™ program is the Company’s primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer’s and other vascular disorders. The Company’s secondary focus is TGF-Beta Shield™, a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit [www.resverlogix.com](http://www.resverlogix.com).

*This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.*

**For further information please contact:**

Theresa Kennedy  
VP, Corporate Communications  
Resverlogix Corp.  
Phone: 604-538-7072  
Fax: 403-256-8495  
Email: [Theresa@resverlogix.com](mailto:Theresa@resverlogix.com)  
Website: [www.resverlogix.com](http://www.resverlogix.com)

**Note to editors:** Ken Lebioda, Senior Vice-President, will be attending the conference and can meet in person with interested media.